Antituberculosis therapy drug-induced liver injury and acute liver failure

Hepatology

Volumn 52, Issue 2, 2010, Pages 798-799

  Devarbhavi, Harshad ^a,b   Dierkhising, Ross ^b,c   Kremers, Walter K ^b,c  

^a ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^b Mayo Clinic College of Medicine   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ATORVASTATIN; BILIRUBIN; CREATININE; DAPSONE; PARACETAMOL; PHENYTOIN; TUBERCULOSTATIC AGENT;

ADULT; FEMALE; HUMAN; LETTER; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTHROMBIN TIME; SCORING SYSTEM; SURVIVOR; TOXIC HEPATITIS; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; LIVER FAILURE, ACUTE; MALE;

EID: 77955704183     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23805     Document Type: Letter

References (8)

1. Kumar R, Shalimar Bhatia V, Sreenivas V, Gupto SD, Panda SK, et al. Antitubercular therapy-induced acute liver failure: magnitude, profile, prognosis and predictors of outcome. HEPATOLOGY 2010;51: 1665-1674.
2. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al., for the Drug-Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135:1924-1934.
3. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. HEPATOLOGY 2005;42:481-489. (Pubitemid 41061102)
4. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, et al., for the Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512-521.
5. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004;10:1018-1023.
6. O'Grady JG, Graeme GJM, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-445. (Pubitemid 19192181)
7. Devarbhavi H, Dierkhsing R, Kremers W, Sandeep MS, Karanth D, Adarsh CK. Single center experience with drug induced liver injury from India: causes, outcome, prognosis, and predictors of molarity. Am J Gastroenterol 2010. In press.
8. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002;166:916-919. (Pubitemid 35193218)